Compare DUO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DUO | ELUT |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | China | United States |
| Employees | N/A | 26 |
| Industry | Real Estate | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 41.9M |
| IPO Year | 2018 | 2020 |
| Metric | DUO | ELUT |
|---|---|---|
| Price | $0.65 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 117.3K | 92.7K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,293,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.83 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.65 | $0.50 |
| 52 Week High | $5.34 | $2.60 |
| Indicator | DUO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 22.69 | 45.11 |
| Support Level | N/A | $0.86 |
| Resistance Level | $1.25 | $0.99 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 3.33 | 24.24 |
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.